{"filing":{"accession_number":"0001437749-26-026351","cik":"0001625101","ticker":"PLSE","company_name":"PULSE BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"plse20260806_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926026351/plse20260806_8k.htm"},"events":[{"id":24658,"run_id":22355,"accession_number":"0001437749-26-026351","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities on August 6, 2026, authorizing the sale of up to $75 million in common stock through an \"at the market\" offering under Rule 415. This is a dilutive equity issuance that provides the company with a capital-raising mechanism and would materially affect existing shareholders through potential dilution. The substantial offering size and explicit authorization to sell shares make this a material capital event.","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25291,"accession_number":"0001437749-26-026351","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities on August 6, 2026, authorizing the sale of up to $75 million in common stock through an \"at the market\" offering under Rule 415. This is a dilutive equity issuance that provides the company with a capital-raising mechanism and would materially affect existing shareholders through potential dilution. The substantial offering size and explicit authorization to sell shares make this a material capital event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:32:07.362687+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25291,"accession_number":"0001437749-26-026351","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities on August 6, 2026, authorizing the sale of up to $75 million in common stock through an \"at the market\" offering under Rule 415. This is a dilutive equity issuance that provides the company with a capital-raising mechanism and would materially affect existing shareholders through potential dilution. The substantial offering size and explicit authorization to sell shares make this a material capital event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:32:07.362687+00:00","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-08-06"}]}